Mirdametinib is approved in the U.S. for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) ...

Merck Animal Health is investing $895 million in a new De Soto facility, which will bring hundreds of jobs to the area. The ...

The neurofibromatosis type 1 market remains niche, but awareness campaigns, increased diagnoses, and treatment adoption, along with ongoing clinical ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

We recently published a list of the 20 Best Dividend Growth Stocks with High Yields. In this article, we are going to take a ...

FRANKFURT: German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 ...

Applied to medicines, price controls would translate into shortages and slow, or non-existent, introduction of new, ...

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

Merck KGaA struck a $3.9 billion deal for SpringWorks Therapeutics. Novartis plans to acquire Regulus Therapeutics for $800 million upfront and up to $1.7 billion overall. Biohaven signed a $600 ...

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to ...

Why is that? That's because big pharmaceutical powerhouse Merck KGaA had agreed to acquire SpringWorks Therapeutics for a purchase price of $47 per share, which represents an equity value of $3.9 ...

According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 ...